# MedTrace Pharma A/S: Phase 3 study completed, 232 enrolled (Coronary Artery Disease)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | MedTrace Pharma A/S |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) |
| NCT ID | NCT05134012 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Coronary Artery Disease |
| Intervention types | drug |
| Target enrollment | 232 |
| Site countries | United States, Canada, Denmark, Germany, Netherlands, Sweden |
| Posted | 2021-11-24 |
| Planned start | 2022-05-08 |
| Event | Completed |
| Event date | 2026-10-02 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 232 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05134012). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.